Ken Griffin Fibrogen Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Fibrogen Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 247,200 shares of FGEN stock, worth $220,008. This represents 0.0% of its overall portfolio holdings.

Number of Shares

247,200

Previous 63,500 289.29%

Holding current value

$220,008

Previous $56,000 935.71%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.73 - $2.73 $275,146 - $1.03 Million	-376,913 Reduced 15.77%	2,013,768 $4.73 Million
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.91 $433,290 - $1.04 Million	1,140,237 Added 91.19%	2,390,681 $2.13 Million
Q3 2023 Nov 14, 2023	BUY	$0.79 - $2.83 $760,353 - $2.72 Million	962,473 Added 334.23%	1,250,444 $1.08 Million
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $723,708 - $5.98 Million	-290,646 Reduced 50.23%	287,971 $777,000
Q1 2023 May 15, 2023	SELL	$15.95 - $25.18 $62,635 - $98,881	-3,927 Reduced 0.67%	578,617 $10.8 Million

Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $7.38 Million - $9.87 Million	556,484 Added 2135.4%	582,544 $9.33 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $706,298 - $904,557	-61,956 Reduced 70.39%	26,060 $339,000
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $457,653 - $747,001	57,639 Added 189.75%	88,016 $930,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $3.37 Million - $4.71 Million	-280,720 Reduced 90.24%	30,377 $365,000
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $3.01 Million - $4.67 Million	303,429 Added 3957.08%	311,097 $4.39 Million
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $371,177 - $713,171	-19,988 Reduced 72.27%	7,668 $204,000
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $1.14 Million - $2.05 Million	-36,880 Reduced 57.15%	27,656 $960,000
Q4 2020 Feb 16, 2021	SELL	$37.09 - $48.97 $3.2 Million - $4.23 Million	-86,327 Reduced 57.22%	64,536 $2.39 Million
Q3 2020 Nov 16, 2020	BUY	$40.47 - $45.5 $2.24 Million - $2.51 Million	55,254 Added 57.79%	150,863 $6.2 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $1.91 Million - $2.52 Million	58,792 Added 159.69%	95,609 $3.88 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $1.76 Million - $3.48 Million	-75,727 Reduced 67.29%	36,817 $1.28 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $7.85 Million - $10.9 Million	-227,141 Reduced 66.87%	112,544 $4.83 Million
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $14.9 Million - $19.5 Million	-402,992 Reduced 54.26%	339,685 $12.6 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $24.6 Million - $38.8 Million	699,154 Added 1606.4%	742,677 $33.6 Million
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $539,615 - $754,806	-12,599 Reduced 22.45%	43,523 $0
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $1.92 Million - $3.04 Million	50,588 Added 914.13%	56,122 $2.6 Million
Q2 2018 Aug 10, 2018	SELL	$44.9 - $64.95 $165,052 - $238,756	-3,676 Reduced 39.91%	5,534 $0
Q1 2018 May 11, 2018	SELL	$45.35 - $61.65 $2.41 Million - $3.27 Million	-53,041 Reduced 85.21%	9,210 $426,000
Q4 2017 Feb 09, 2018	BUY	$41.95 - $60.1 $1.73 Million - $2.48 Million	41,203 Added 195.76%	62,251 $2.95 Million
Q3 2017 Nov 09, 2017	BUY	$33.4 - $53.9 $703,003 - $1.13 Million	21,048	21,048 $1.13 Million

Others Institutions Holding FGEN

# of Institutions

120

Shares Held

62.2M

Call Options Held

1.54M

Put Options Held

221K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $83.4M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account